TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07439510: A Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Codabakalner in Male Participants With Full Mutation Fragile X Syndrome and Adult Participants Wi

Sponsor: Spinogenix · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 120 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,961,280

Rescue Site Savings

+$8,546,344

Unlock Full NCT07439510 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07439510 Rescue Dossier →